First Tracks Biotherapeutics Inc (TRAX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$35.00

From 52W high−24.29%

Volume1.43M

Market cap$1.30B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$35.00

From 52W high

−24.29%

Volume

1.43M

Market cap

$1.30B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.5x

P/E (TTM)

—

RSI (14)

52.6

MomentumView details →

1D Return

+5.28%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

7.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−98.40%

ROA (TTM)

−90.69%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+5.28%

YTD Return

—

1Y Return

—

RSI (14)

52.6

vs 50D SMA

−6.37%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

14.28x

Quick Ratio

14.28x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.95

EPS Surprise

−28.38%

Beats (12Q)

0/12

Next Q EPS Est

−$0.84

Avg Surprise (4Q)

−28.38%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−173.50M

Op. CF (TTM)

−148.12M

Next earningsNov 11, 2026 →

Latest newsMore news →

First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 common shares to institutional investors in a private placement at $32.75 per share, anticipating approximately $200 million in gross proceeds before fees and expenses.5d ago

First Tracks Biotherapeutics, Inc. announced that it will host an investor call and webcast on October 12, 2026, to review top-line data from Cohort 1 of its Phase 1b ANB033 trial in celiac disease.8d ago

Similar companies

ORIC Pharmaceuticals, Inc.ORIC Inhibrx Biosciences, Inc.INBX Taysha Gene Therapies, Inc.TSHA Tyra Biosciences, Inc.TYRA Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK ST嘉必优688089.SH Find similar companies →

Latest newsMore news →

First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 common shares to institutional investors in a private placement at $32.75 per share, anticipating approximately $200 million in gross proceeds before fees and expenses.5d ago First Tracks Biotherapeutics, Inc. announced that it will host an investor call and webcast on October 12, 2026, to review top-line data from Cohort 1 of its Phase 1b ANB033 trial in celiac disease.8d ago